In summary, we suggest that targeting the CCR10/CCL27 crosstalk in the myeloma microenvironment could contribute to the development of tailored therapeutic interventions bringing multiple myeloma to a chronic, manageable disease or even to cure. This evidence concerns the gene CCL27 and plasma cell myeloma.